Wegovy Pill Dosage: UK Schedule, Administration and Key Clinical Facts

Wegovy pill dosage follows a carefully structured escalation schedule designed to minimise side effects while supporting effective weight management. The oral tablet formulation of semaglutide, approved by the MHRA in June 2026, starts at 1.5 mg once daily and increases monthly through 4 mg and 9 mg before reaching the 25 mg maintenance dose. Understanding how and when to take each strength, what to do if a dose is missed, and how the tablet differs from the Wegovy injection is essential for safe, effective treatment. This article explains the full UK dosage schedule, administration rules, and key clinical considerations.

What the Wegovy Pill Dosage Schedule Is in the UK

The UK Wegovy pill dosage starts at 1.5 mg once daily, escalating monthly to 4 mg, 9 mg, and then 25 mg as the standard maintenance dose, with a minimum of one month at each step.

The Wegovy pill dosage used in the UK follows a step-by-step escalation schedule rather than starting immediately at the highest strength. Wegovy tablets contain semaglutide, a GLP-1 receptor agonist used for weight loss and weight maintenance alongside a reduced-calorie diet and increased physical activity. The tablet formulation was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in June 2026 for eligible adults with obesity, or adults who are overweight and have at least one weight-related health problem.

According to the current UK Summary of Product Characteristics (SmPC), the starting dose is 1.5 mg once daily. The standard schedule is:

• Month 1: 1.5 mg once daily

• Month 2: 4 mg once daily

• Month 3: 9 mg once daily

• Month 4 onward: 25 mg once daily as the maintenance dose

There must be a minimum of one month at each dose level before moving to the next step.^[1][3] This means the standard escalation to 25 mg takes at least three months from starting treatment. However, patients should not change doses for themselves. The SmPC states that, if needed, treatment can be maintained at the previous dose level, so a prescriber may decide that someone should stay on a lower strength for longer.

The maximum recommended single daily dose is 25 mg.^[1][3] Wegovy tablets should be used as one tablet per day only. Lower-strength tablets should not be combined to try to create the effect of a higher dose. Taking several tablets is not an approved substitute for one prescribed higher-strength tablet.

The lower strengths are important parts of treatment even though 25 mg is the standard maintenance dose. Dose escalation gives the body time to adapt to semaglutide and is particularly relevant because gastrointestinal side effects such as nausea, diarrhoea, constipation and vomiting are common. The aim is not to reach the highest dose as quickly as possible, but to follow a clinically appropriate schedule under prescriber supervision.

It is also important not to confuse the oral strengths with Wegovy injections. The tablet uses 1.5 mg, 4 mg, 9 mg and 25 mg strengths, whereas the injection follows a separate once-weekly schedule. A 25 mg tablet is not simply "stronger" than a 2.4 mg injection because the formulations are administered and absorbed differently.

Why the Wegovy Pill Dose Is Increased Gradually

Gradual dose escalation allows the body to adapt to semaglutide and reduces the risk of gastrointestinal side effects such as nausea, vomiting, and diarrhoea, which are most common at the start of treatment.

The gradual Wegovy pill dosage schedule is known as dose escalation or titration. It is a deliberate part of treatment. Semaglutide acts on GLP-1 receptors involved in appetite regulation and can help people feel fuller, less hungry and experience fewer food cravings.^[10][11] It also affects the gastrointestinal system, which helps explain why digestive side effects are among the most frequently reported problems during treatment.

The UK SmPC starts oral Wegovy at 1.5 mg once daily and requires at least one month at each stage before progression to 4 mg, 9 mg and finally 25 mg. The MHRA lists nausea, diarrhoea, constipation and vomiting among the most common side effects, while European regulatory information notes that gastrointestinal effects occurred mainly near the start of treatment.^[1][2]

A person should not increase their dose early because they are not yet losing as much weight as expected. Weight response varies, and the lower starting doses are part of the approved regimen. Taking more than prescribed may increase the risk of adverse effects and does not replace a clinical review.

Equally, reaching a calendar date does not mean that a dose increase must happen regardless of tolerability. The current UK prescribing information allows the dose to be maintained at the previous dose level if needed. Someone experiencing significant side effects should speak to their prescriber rather than pushing ahead, stopping without advice or altering the number of tablets taken.

Gastrointestinal symptoms can also lead to dehydration, particularly when vomiting or diarrhoea is persistent. The patient leaflet advises people to drink enough fluids and highlights that dehydration is especially important for those with kidney problems. Severe or persistent symptoms should be assessed by a healthcare professional.

This distinction matters for questions such as "Can I stay on 9 mg Wegovy pills?" The safe answer is not to self-adjust. The SmPC permits remaining at the previous dose level when needed, but that decision should form part of the prescribed treatment plan. The correct dose at any point depends on the stage of escalation, tolerability and clinical judgement.

How to Take Each Daily Wegovy Dose Correctly

Each Wegovy tablet must be swallowed whole on an empty stomach after an 8-hour fast, with up to 120 mL of plain water, then followed by a 30-minute wait before eating, drinking, or taking other oral medicines.

Getting the Wegovy pill dosage right is only part of using the medicine correctly. Oral semaglutide has specific administration instructions because food, water volume and the timing of other oral medicines can affect absorption.

The current UK SmPC states that Wegovy tablets should be taken once daily on an empty stomach after fasting for at least 8 hours.^[1][2] Many people may find first thing in the morning the simplest time after an overnight fast, but the essential point is to follow the prescribed fasting instructions.

The tablet should be:

• swallowed whole

• taken with a small amount of plain water, up to 120 mL, around half a glass

• followed by a wait of at least 30 minutes before eating

• followed by a wait of at least 30 minutes before drinking

• followed by a wait of at least 30 minutes before taking other oral medicines

The tablet should not be split, crushed or chewed. The SmPC notes that it is not known whether doing so affects semaglutide absorption.^[1][3] Waiting less than 30 minutes before food, drink or another oral medicine can reduce absorption.

These rules are important because oral semaglutide is absorbed differently from an injection. The UK prescribing information describes oral absorption as variable, which is another reason tablet doses should not be directly compared with the milligram strengths of weekly Wegovy injections.

Patients who take other morning medicines should discuss timing with their prescriber or pharmacist rather than improvising. The official instructions require the 30-minute interval before other oral medicines, while another medicine may have its own timing requirements.

If a daily dose is missed, the UK SmPC says the missed dose should be skipped and the next dose taken the following day. Patients should not take an extra tablet to make up for the missed dose. This differs from instructions used for some weekly injectable medicines, so injection advice should not be applied to the pill.

Where several doses have been missed, or treatment has been interrupted for longer, it is sensible to contact the prescriber for individual advice before changing strength or attempting to compensate for missed tablets. The key rule is to resume or adjust treatment according to professional guidance, not by doubling up.

Lower Doses, Maintenance Dosing and Switching From Wegovy Injections

The standard maintenance dose is 25 mg once daily, but prescribers may keep patients at a lower dose if tolerability requires it; switching from the injection to the tablet requires clinical supervision due to differences in absorption.

A common question is whether everyone has to reach 25 mg once daily. Under the standard UK schedule, treatment is escalated from 1.5 mg to 4 mg, then 9 mg and finally 25 mg, which the SmPC identifies as the maintenance dose. However, the same prescribing information states that, if needed, the dose can be maintained at the previous dose level.

That provides clinical flexibility, particularly where tolerability is an issue. It does not mean patients should independently remain on a lower dose, move backwards, skip a step or change strength according to appetite or short-term changes on the scales.

The roles of the four strengths can be summarised as follows:

• 1.5 mg: the approved starting dose

• 4 mg: the first escalation step after at least one month

• 9 mg: the next escalation step after at least one month at 4 mg

• 25 mg: the standard maintenance dose and maximum recommended single daily dose

There is also a difference between staying longer at a dose and taking multiple tablets. The SmPC explicitly says oral semaglutide should always be used as only one tablet per day and that more than one tablet should not be used to achieve a higher dose.

Switching between a Wegovy injection and the Wegovy pill requires particular care. The UK SmPC says the effect of switching between oral and injected semaglutide cannot easily be predicted because oral semaglutide has greater variability in absorption than subcutaneous semaglutide.^[1][6]

For one specific situation, the prescribing information gives a defined transition: patients treated with semaglutide injection 2.4 mg once weekly can be transitioned to semaglutide tablets 25 mg once daily, starting the tablets one week after the last injection. This is not a general conversion rule for every Wegovy injection strength. Someone using a lower injection dose should not assume they can automatically move to a particular tablet strength.

The same caution applies when switching from another medicine such as Mounjaro (tirzepatide). Tirzepatide is a different active substance, and there is no simple milligram-for-milligram conversion to a Wegovy pill dose. Switching should be based on a clinical assessment rather than an online calculator or another patient’s schedule.

Wegovy tablets are prescription-only and are licensed for adults who meet the relevant weight-management criteria. In the UK, this includes adults with an initial BMI of 30 kg/m² or above, or a BMI from 27 kg/m² to below 30 kg/m² with at least one weight-related comorbidity. The tablets are used alongside a reduced-calorie diet and increased physical activity.

In summary, the standard Wegovy pill dosage begins at 1.5 mg once daily, rises no faster than monthly through 4 mg and 9 mg, and reaches 25 mg once daily as the maintenance dose. Each tablet must be taken according to the fasting and timing instructions, missed doses should be skipped rather than doubled, and changes in strength or formulation should be clinically supervised. Patients should follow the exact strength prescribed and should not combine, split or self-adjust tablets.

Scientific References

1. Wegovy 25 mg tablets – Summary of Product Characteristics.
2. First GLP-1 tablet for weight loss approved in the UK.
3. Wegovy 1.5 mg tablets – Package Leaflet (Patient Information Leaflet).
4. Wegovy – opinion on variation to marketing authorisation (CHMP positive opinion, 21 May 2026).
5. Wegovy EPAR – Product Information.
6. Rybelsus EPAR – Product Information (oral semaglutide SmPC).
7. Rybelsus – European Public Assessment Report.
8. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics.
9. Semaglutide: a medicine to manage type 2 diabetes or treat obesity.
10. Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.
11. Integrated Genetic and Protein Mechanisms Underlying Glucagon-like Peptide-1 Receptor Agonists in Treating Diabetes Mellitus and Weight Loss.

Frequently Asked Questions